Substrate of CYP 3A4. Two references stating non-porphyrinogenicity. Occasional clinical experience of non-porphyrinogenicity

(To be edited, initial data ST OCT 04) Cholesterol lowering clofibrate derivative, dose 600 mg/d. 95 % absorbed from the gut. Metabolized by CYP 3A4 . No data pointing to CYP-induction. Thunell, patient report (n=1): tolerated. Andersson, patient report (n=3): tolerated. South African list: use with care French list: authorized

Uneventful use reported in 9 patients with acute porphyria.